MedTrace Logo

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

NCT06855095 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-03-03

No results posted yet for this study

Summary

According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.

Conditions

  • Neuroendocrine Tumors
  • Neuroendocrine Tumor Grade 1
  • Neuroendocrine Tumor Grade 2
  • Neuroendocrine Neoplasm

Interventions

DRUG

Somatostatin analog

Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).

Sponsors & Collaborators

  • Neuroendocrine Tumor Research Foundation

    collaborator UNKNOWN

  • The Netherlands Cancer Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2027-01-01
Completion
2027-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06855095 on ClinicalTrials.gov